What is droxidopa used for, and how should it be dosed and monitored in adults with neurogenic orthostatic hypotension?

Droxidopa for Neurogenic Orthostatic Hypotension

Droxidopa is FDA-approved and beneficial for treating symptomatic neurogenic orthostatic hypotension (nOH) in adults with primary autonomic failure (Parkinson's disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. 1

Indications and Patient Selection

Droxidopa specifically treats orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in patients with symptomatic nOH. The drug improves symptoms in Parkinson disease, pure autonomic failure, and multiple system atrophy, and may reduce falls according to small studies 2.

Use droxidopa after non-pharmacological measures have been implemented, including physical counter-pressure maneuvers, compression garments (thigh-high or abdominal), acute water ingestion (≥240 mL), and increased salt/fluid intake when appropriate 2.

Dosing Protocol

Starting Dose

• Begin with 100 mg three times daily: upon arising in the morning, at midday, and in the late afternoon at least 3 hours prior to bedtime 1
• Take consistently either with food or without food
• Swallow capsules whole

Titration Schedule

• Increase by 100 mg three times daily every 24-48 hours based on symptomatic response 1
• Maximum dose: 600 mg three times daily (1,800 mg total daily dose)
• Monitor supine blood pressure before initiating and after each dose increase

Important caveat: Real-world data shows that 53% of patients use customized titration schedules (slower than label recommendations), resulting in lower daily dosages but potentially shorter treatment persistence 3. However, rapid titration under supervision has proven safe even in severely ill hospitalized patients 4.

Critical Monitoring Requirements

Supine Hypertension (Primary Safety Concern)

• Elevate the head of the bed when resting or sleeping - this is the most important intervention to reduce supine hypertension risk 1
• Measure blood pressure in both supine position AND in the recommended head-elevated sleeping position
• If supine hypertension persists despite head elevation, reduce or discontinue droxidopa
• Uncontrolled supine hypertension may increase cardiovascular risk, particularly stroke 1

Blood Pressure Response

Standing systolic BP typically increases by approximately 11 mm Hg, while supine systolic BP increases by approximately 8 mm Hg 5. After 12 weeks, mean increases of 15.5 mm Hg systolic and 7.8 mm Hg diastolic have been observed 6.

Duration of Treatment and Reassessment

FDA approval notes that effectiveness beyond 2 weeks has not been established 1. However, recent evidence demonstrates sustained benefit:

• A 12-week open-label study showed continued significant improvements in symptoms and activities of daily living 6
• Periodically reassess continued effectiveness as required by the FDA label 1
• Treatment persistence data shows 65% of patients continue therapy at 6 months 4, with median persistence of 303 days in real-world use 7

Common Adverse Effects

The most frequent side effects (>5%) include 1:

• Headache (7.4%)
• Dizziness (3.7%)
• Nausea
• Hypertension

Use and titration may be limited by supine hypertension, headache, dizziness, and nausea 2.

Important Drug Interactions

Carbidopa use in Parkinson's disease patients may decrease droxidopa effectiveness 2. This occurs because carbidopa is a DOPA decarboxylase inhibitor, and droxidopa requires decarboxylation to convert to norepinephrine. Dose adjustments may be necessary 1.

Special Populations and Contraindications

• Contraindicated in patients with hypersensitivity to droxidopa or its ingredients 1
• Use caution in patients with ischemic heart disease, arrhythmias, or congestive heart failure, as droxidopa may exacerbate these conditions 1
• Breastfeeding not recommended 1
• Cannot provide dosing recommendations for patients with GFR <30 mL/min 1

Comparative Positioning

Droxidopa and midodrine are both considered beneficial first-line pharmacological options for neurogenic OH 2, 8. Real-world data suggests droxidopa users demonstrate 16% greater treatment persistence compared to midodrine users and remain on treatment longer (median 303 vs 172 days) 7. Fludrocortisone should be used before droxidopa when supine hypertension is already present 2.

Practical Implementation Algorithm

1. Implement non-pharmacological measures first (compression garments, physical maneuvers, water boluses)
2. Start droxidopa 100 mg three times daily (morning, midday, late afternoon ≥3 hours before bed)
3. Elevate head of bed to mitigate supine hypertension risk
4. Measure supine BP (in head-elevated position) before each dose increase
5. Titrate by 100 mg TID every 24-48 hours to symptomatic response (max 600 mg TID)
6. Reassess effectiveness at 2 weeks, then periodically thereafter
7. If supine hypertension develops: ensure head elevation compliance, consider dose reduction, or discontinue if unmanageable